The treatment of glioblastoma multiform (GBM) is a challenge for the biomedical research since cures remain elusive. Its current therapy, consisted on surgery, radiotherapy, and concomitant chemotherapy with temozolomide (TMZ), is often un-effective. Here, we proposed the use of zoledronic acid (ZOL) as a potential agent for the treatment of GBM. Our group previously developed self-assembling nanoparticles, also named PLCaPZ NPs, to use ZOL in the treatment of prostate cancer. Here, we updated the previously developed nanoparticles (NPs) by designing transferrin (Tf)-targeted self-assembling NPs, also named Tf-PLCaPZ NPs, to use ZOL in the treatment of brain tumors, e.g., GBM. The efficacy of Tf-PLCaPZ NPs has been evaluated in different GBM cell lines and in an animal model of GBM, in comparison with PLCaPZ NPs and free ZOL. Tf-PLCaPZ NPs were characterized by a narrow size distribution and a high incorporation efficiency of ZOL. Moreover, the presence of Tf significantly reduced the hemolytic activity of the formulation. In vitro, in LN229 cells, a significant uptake and cell growth inhibition after treatment with Tf-PLCaPZ NPs was achieved. Moreover, the sequential therapy of TMZ and Tf-PLCaPZ NPs lead to a superior therapeutic activity compared to their single administration. The results obtained in mice xenografed with U373MG, revealed a significant anticancer activity of Tf-PLCaPZ NPs, while the tumors remained unaffected with free TMZ. These promising results introduce a novel type of easy-to-obtain NPs for the delivery of ZOL in the treatment of GBM tumors.
INTRODUCTION
Glioblastomas (GBM) are highly aggressive brain tumors with poor clinical outcome. Despite a broad range of new and more specific treatment strategies, the therapy of GBM remains challenging and tumors relapse in all the cases. With the increase in the population affected by brain tumours, it has become extremely important to develop a dosage form capable to sensitize these tumors to the current treatments. 1 2 Zoledronic acid (ZOL) belongs to the nitrogen containing bisphosphonates (NBPs), agents of choice for the treatment of bone metastases. ZOL inhibits the farnesyl pirophosphate synthase (FPPS), the upstream enzyme involved in the cholesterol synthesis chain, with consequent inhibition of cell proliferation, 3 differentiation, 4 adhesion 5 and tumorogenesis. 6 7 Due to these pharmacodynamic effects, ZOL has widely demonstrated a direct anti-proliferative action on human tumor cells in vitro. 8 Unfortunately, ZOL has a very short plasma half-life and tends to accumulate in the bone, which results in far below therapeutically effective concentrations that reach tumor tissues. 9 10 Therefore, new approaches aimed at increasing ZOL plasma half-life and achieve effective concentrations of ZOL in different districts, such as tumors, must be designed. 7 To address this problem, previously we proposed new nanoplatform-based formulation for the delivery of ZOL in solid tumors. 11 In particular, ZOL was firstly complexed with calcium phosphate NPs (CaP NPs) and then mixed with PEGylated cationic liposomes to form a lipid and PEGylated shell. The developed formulation exhibited optimal physical characteristics together with the possibility to be prepared immediately before use, overcoming problems of stability during the storage which often hamper the scale-up of many promising drug delivery systems. 11 In addition, in in vivo model of prostate adenocarcinoma, a strong and significant inhibition of the tumor growth was demonstrated. 12 Here, in order to investigate the potential of ZOL in the treatment of GBM tumours, we upgraded the previously developed NPs by introducing the transferrin (Tf) as a ligand on the NP surface to improve the efficacy and specificity of therapeutics in GBM cells. 13 14 In particular, we propose the introduction of Tf on the surface of the nanoparticles with the double aim, namely to target the Tf-overexpressing GBM cells and to facilitate the BBB crossing.
Thus, in this manuscript, we updated the previously developed ZOL-encapsulation NPs and we proposed ZOL-encapsulating Tf-modified self-assembling NPs (Tf-PLCaPZ NPs). The effect of Tf-PLCaPZ NPs on the growth inhibition and cell death was studied on different GBM cells. In a second phase, the potential of a combination therapy of Tf-PLCaPZ NPs and temozolamide (TMZ), the anti-cancer agent currently used in the treatment of GBM, was investigated. Finally, the in vivo therapeutic potential of Tf-PLCaPZ NPs and its superiority compared to TMZ in mice xenografted with U373MG, a GBM cell line was investigated.
MATERIALS AND METHODS

Materials
Unless otherwise stated, all chemicals were from Sigma-Aldrich (Saint Louis, MO, USA). 1,2-dioleoyl-3-trimethylammonium-propane chloride (DOTAP) and 1,2-diacyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene-glycol) 2000 ] (DSPE-PEG 2000 were obtained from Lipoid GmbH (Cam, Switzerland). BODIPY ® FL DHPE (N-(4,4-Difluoro-5,7-Dimethyl-4-Bora-3a,4a-Diaza-s-Indacene-3-Propionyl)-1,2-Dihexadecanoyl-snGlycero-3-Phosphoethanolamine, Triethylammonium Salt was purchased from Life Technology (Eugene, OR, USA). RPMI 1640, DMEM and FBS were purchased from FlowLaboratories (Milan, Italy). Tissue culture plasticware was from Becton Dickinson (Lincoln Park, NJ, USA). Rabbit antisera raised against -tubulin and CD71 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ZOL was kindly provided by Novartis (Basilea, Switzerland).
Preparation of Self-Assembled NPs Functionalized with Human Transferrin
In this study, we modified the surface of the previously developed PLCaPZ NPs 11 with human Tf. The NP preparation was schematically represented in Figure 1 . In detail, Tf modified PLCaPZ NPs were prepared as follows. In a first step, PEGylated cationic liposomes consisting of DOTAP/chol/DSPE-PEG 2000 (1:1:0.5 weight ratio) were prepared by hydration of a thin lipid film followed by extrusion. The lipid mixture was dissolved in 1 ml of a mixture chloroform/methanol (2:1 v/v). The organic solution was removed by N 2 , and the film was further dried under vacuum. Then, the lipid film was hydrated with 1 ml of sterile water and the resulting dispersion was extruded using a thermobarrel extruder system. In a second step, pre-formed PEGhylated cationic liposomes were mixed with human Tf (10 mg/ml in phosphate buffer at pH 7.4) at a volume ratio of 1:1, at room temperature for 15 min, obtaining the so-called Tf-PEGylated cationic liposomes. Separately, CaP NPs/ZOL complexes (CaPZ) were prepared as previously described by Salzano et al. 11 Briefly, an aqueous solution of calcium chloride (18 mM) was added, dropwise and under magnetic stirring, to an aqueous solution on dibasic hydrogen phosphate (10.8 mM). The pH of both solutions was adjusted beforehand to 9.5 with NaOH 0.1 M. CaP NPs were obtained by filtration of the suspension through a 0.22 m filter. The dispersion was then mixed with an aqueous solution of ZOL (50 mg/ml of ZOL in phosphate buffer at pH 9.5), resulting in CaPZ. Finally, Tf-PLCaPZ NPs were prepared by mixing Tf-PEGylated cationic liposomes complex with CaPZ, at a volume ratio of 1:0.5, at room temperature for 15 min. Plain Tf-modified NPs (Tf-PLCaP NPs), ZOL-encapsulating NP without Tf (PLCaPZ NPs) and plain PLCaP NPs were prepared similarly. Each formulation was prepared in triplicate. For intra-cellular penetration studies, fluorescently labeled NPs containing 0.1% (w/w) of BODIPY ® FL DHPE were prepared similarly by adding the fluorescent cholesterol in the lipid mixture of DOTAP/chol/DSPE-PEG 2000 during the liposomes preparation.
Size and Zeta Potential of Tf-PLCaPZ NPs
The mean diameter of NPs was determined at 20 C by photon correlation spectroscopy (PCS) (N5, Beckman Coulter, Miami, USA). Each sample was diluted in deionizer/filtered water (0.22 m pore size, polycarbonate filters, MF-Millipore, Microglass Heim, Italy) and analyzed with detector at 90 angle. As measure of the particle size distribution, polydispersity index (P.I.) was used. For each batch, mean diameter and size distribution were the mean of three measures. For each formulation, the mean diameter and P.I. were calculated as the mean of three different batches.
The zeta-potential ( ) of the NPs surface was measured in water by means of a Zetasizer Nano Z (Malvern, UK). Data of were collected as the average of 20 measurements. ZOL analysis was carried out by reverse phase high performance liquid chromatography (RP-HPLC) as previously reported.
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ZOL Incorporation in Tf-PLCaPZ NPs
The incorporation efficiency of ZOL in Tf-PLCaPZ NPs was determined as follows: 1 ml of NPs dispersion was ultracentifugated (Optima Max E, Beckman Coulter, USA) at 80.000 rpm at 4 C for 40 min. Supernatant was carefully removed and analyzed to determine un-incorporated ZOL concentration by RP-HPLC. The results have been expressed as complexation efficiency, calculated as the ratio between the amount of ZOL present in the supernatant and the amount of ZOL theoretical loaded.
Tf Binding to the Tf-PLCaPZ NPs
The amount of Tf linked to the NPs was determined by Bradford assay method, as previously reported by Georgiou et al. 15 For the quantification of Tf, a calibration curve obtained with a Tf standard solutions ranging from 0.01 to 1 mg/mL was used. Briefly, 50 L of Tf solution was mixed with 950 L of Bradford reagent. After 10 minutes of incubation at room temperature, the absorbance of the mixture was measured at 595 nm using UV-vis spectrophotometer (UV-1800 Shimadzu). The amount of free Tf, not linked to the NPs, was measured in the supernatant obtained after ultracentrifugation of the NPs at 80.000 RPM for 30 minutes at 4 C. The amount of Tf associated to the NPs was quantified by comparing the total amount of Tf added in the preparation to the amount of un-bound Tf in the supernatant.
Hemolysis Assay
The hemolysis assay has been performed on fresh human blood as previously reported by Cheng et al. 13 with slight modifications. The erythrocytes were collected by centrifugation at 2000 rpm for 15 min, and then washed three times with phosphate buffered saline (PBS) buffer at pH 7.4. The stock dispersion was prepared by mixing 3 mL of centrifuged erythrocytes into 11 mL of PBS. Then, 100 l of stock dispersion were added to 1 mL of NPs dispersions, prepared as reported above and incubated for 4 h at 37 C under slightly agitation. The percentage of hemolysis was determined by UV-vis analysis of the supernatant at 541 nm absorbance after centrifugation at 13,000 rpm for 15 min. Plain Tf-PLCaP NP, PLCaPZ NP without Tf, plain Tf-PLCaP NP and ZOL free at a final concentration of 20 g were used as controls. One milliliter of PBS was used as the negative control with 0% hemolysis, and 1 mL of deionized water was used as the positive control with 100% hemolysis. All hemolysis data were calculated using the following formula:
Hemolysis % = Abs − Abs 0 / Abs 100 − Abs 0 * 100 Cell Lines, Protein Extraction and Western Blotting Transferrin receptor (CD71) was evaluated in three different cell lines of human GBM, LN229, U87 MG and U373 MG by Western Blotting method.
GBM cell lines were provided by Professor C. Leonetti (Department of Experimental Oncology, Regina Elena National Cancer Institute IRCCS -Rome) and were grown in medium as suggested by ATCC in a humidified incubator containing 5% CO 2 at 37 C.
Cell cultures were washed twice with ice-cold PBS/BSA, scraped, and centrifuged for 30 min at 4 C in 1 ml of lysis buffer (1% Triton, 0.5% sodium deoxycholate, 0.1 M NaCl, 1 mM EDTA, pH 7.5, 10 mM Na 2 HPO 4 , pH 7.4, 10 mM PMSF, 25 mM benzamidin, 1 mM leupeptin, 0.025 U/ml aprotinin). Equal amounts of cell proteins, assessed by Lowry assay using bovine serum albumin as standard, were separated by SDS-PAGE. The proteins on the gels were electrotransferred to nitrocellulose and reacted with the different antibodies as previously shown 17 by Trans blot turbo (BIO-RAD). Membranes were washed in T-TBS (10 mM Tris, pH 8.0, 150 mM NaCl, 0.05% Tween 20) , and blocked with T-TBS supplemented with 5% non-fat dry milk. Then, membranes were incubated with primary antibody at a dilution of 1:1,000 (anti-CD71, Santa Cruz Biotechnology) in T-TBS and 5% non-fat dry milk, washed, and incubated with horseradish peroxide-conjugated secondary antibody at a dilution of 1:2,000 (anti-mouse, Immunoreagent). Blots were then developed using enhanced chemiluminescence detection reagents (SuperSignal West Pico, Pierce) and exposed to X-ray film. The bands derived from western blotting were scanned with a laser scanner (Epson 1260) and their intensities were quantified with Image J software (NIH). Membranes were normalized with a polyclonal antibody against tubulin protein (GTU-88) (Sigma Aldrich). The error bars shown in the histograms represent the standard deviation from the mean of different densitometric scanning in at least three different experiments.
Evaluation of Tf Expression by FACS Analysis
The cells were fixed for 20 minutes with a 3% PFA solution and permeabilized for 10 minutes with 0.1% (v/v) Triton X-100 in PBS at room temperature. To prevent nonspecific interactions of antibodies, the cells were treated for 2 hr in 5% (w/v) BSA in PBS, then the cells were incubated with a specific mouse monoclonal Ab raised against CD71 (1:50 in blocking solution, 3% BSA in TBS-Tween 0.1%) for 2 hours at 37 C. After 6 h and 72 h of incubation of LN229 cells with fluorescently labeled NPs, the cells were fixed for 20 minutes with a 3% (w/v) paraformaldehyde (PFA) solution and permeabilized for 10 minutes with 0.1% (w/v) Triton X-100 in phosphate-buffered saline (PBS) at room temperature. To prevent nonspecific interactions of antibodies, the cells were treated for 2 hr in 5% bovine albumin serum (BSA) in PBS, then the cells were incubated with a specific mouse monoclonal Ab raised against vimentin (1:1,000 in blocking solution, 3% (w/w) BSA in TBSTween 0.1%, Sigma) for 2 hours at 37 C. After several washes the cells were incubated with a secondary IgG goat anti-mouse antibody (Alexa Fluor 633, Life Technologies, Carlsbad, CA) diluted 1:1,000 in blocking solution for 1 h at room temperature. The slides were mounted on microscope slides by Mowiol. The analyses were performed with a Zeiss LSM 510 microscope equipped with a planapochromat objective X 63 (NA 1.4) in oil immersion. The fluorescences of the Alexa 488 and Alexa 633 were collected in multi-track mode using BP505-530 and LP650 as emission filters, respectively.
Confocal Microscopy Analysis of Double Immunofluorescence LN229 cells were treated with free ZOL or the different NPs formulations at a concentration equal to their IC 50 at 72 h. The cells were fixed for 20 minutes with a 3% PFA solution and permeabilized for 10 minutes with 0.1% (v/v) Triton X-100 in PBS at room temperature. To prevent nonspecific interactions of antibodies, the cells were treated for 2 hr in 5% (w/v) BSA in PBS, then the cells were incubated with a specific mouse monoclonal Ab raised against Vimentin (1:1000 in blocking solution, 3% BSA in TBSTween 0.1%, mouse, Sigma) for 2 hours at 37 C.
After several washes the cells were incubated with a secondary IgG goat anti-mouse antibody (Alexa Fluor 633, Life Technologies, Carlsbad, CA) diluted 1:1,000 in blocking solution for 1 h at room temperature. Subsequently, the cells were washed with PBS and incubated with specific rabbit polyclonal Ab against either glial fibrillary acidic protein (GFAP) (Ab7260, Abcam, Cambridge, United Kingdom) or the oligodendrocyte lineage genes 2 (Olig2) (Ab77953, Abcam, Cambridge, United Kingdom) diluted 1:1,000 in blocking solution, at 4 C o/n.
After additional washes, the cells were incubated with both a secondary IgG goat anti-mouse antibody (Alexa Fluor 633, Life Technologies, Carlsbad, CA) and a goat polyclonal anti-rabbit antibody (Alexa 488, Life Technologies, Carlsbad, CA) diluted 1:1,000 in blocking solution for 1 hour at room temperature. The slides were mounted on microscope slides by DAPI. The analysis was performed with a Zeiss LSM 510 microscope equipped with a plan-apochromat objective X 63 (NA 1.4) in oil immersion. The fluorescences of the Alexa 488 and Alexa 633 were collected in multi-track mode using BP505-530 and LP650 as emission filters, respectively.
Cell Proliferation by MTT Assay
After trypsinization, all cell lines were plated in 100 L of medium in 96-well plates at a density of 2 × 10 3 cells/well. One day later the cells were treated with free ZOL, Tf-PLCaPZ NPs, plain Tf-PLCaP NPs, PLCaPZ NPs and plain PLCaP NPs at concentrations ranging of ZOL from 0,78 to 120 M in fresh medium for a 72 h time course. Cell proliferation was evaluated by MTT assay as previously described. 17 
TMZ Combination Studies
For the evaluation of the synergistic effect between the different NP formulations or free ZOL to TMZ on the growth inhibition of GBM cells, the cells were seeded in 96-multiwell plates at the density of 2 × 10 3 cells/well. After 24 h of incubation at 37 C the cells were treated with different concentrations of Tf-PLCaPZ NPs, PLCaPZ NPs, free ZOL, TMZ. Alternatively, cells were treated simultaneously with TMZ and NP formulations or sequentially with TMZ followed by NP formulations and conversely. The evaluation of synergism was performed using dedicated software, CalcuSyn (Biosoft, Ferguson, MO), which measures the interaction between the drugs by calculating the indexes of combination (CIs). CI values <1, 1 and >1 indicate synergism, additive and antagonism, respectively. Drug combination studies were based on concentration-effect curves generated as a plot of the fraction of unaffected (surviving) cells versus drug concentration after 72 h of treatment. Assessment of synergy was performed quantifying the drug interaction by the Calcusyn computer program (Biosoft, Ferguson, MO). Furthermore, we analyzed the specific contribution of the different NPs, free ZOL and TMZ on the cytotoxic effect of the combinations by calculating the potentiation factor (PF), defined as the ratio of the IC 50 of either NPs, free ZOL and TMZ alone to the IC 50 of the different combinations; a higher PF indicates a greater cytotoxicity.
Flow Cytometry Analysis of Apoptosis and Autophagy
A BD FACS Calibur fluorescent-activated flow cytometer and the BD CellQuest software (BD Biosciences) were used to perform flow cytometry analysis of apoptosis and autophagy. 18 Annexin V-FITC (fluorescein isothiocyanate) was used in conjunction with a vital dye, propidium iodide (PI), to distinguish apoptotic (Annexin V-FITC positive, PI negative) from necrotic (Annexin V-FITC positive, PI positive) cells. Briefly, cells were incubated with Annexin V-FITC (MedSystems Diagnostics, Vienna, Austria) and propidium iodide (Sigma, Milan, Italy) in a binding buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2.5 mM CaCl 2 ) for 30 min at room temperature, washed and resuspended in the same buffer. Analysis of apoptotic cells was performed by flow cytometry (FACScan, Becton-Dickinson). For each sample, 2 × 10 4 events were acquired. Analysis was carried out by triplicate determination on at least three separate experiments.
Toxicity of the NPs on GM-CFUs
A major goal in the preclinical drug development is to predict whether new agents or new formulations will be clinically toxic to the bone marrow. Bone marrow is critically sensitive to many cytotoxic agents and myelotoxicity represents one of the limitations to the use of full doses of antineoplastic drugs, including ZOL. For these reasons, we compared the toxicity of ZOL and Tf-PLCaPZ NPs on human bone marrow by using the well-validated CFU-GM assay. Human bone marrow cells were treated in vitro with ZOL either free or encapsulated in Tf-PLCaPZ NPs at doses from 0.0001 to 100 M and surviving fractions were determined. As it is evident from Figure 5 , the encapsulation significantly reduced the myelotoxicity of ZOL. In fact, the interpolation on the curve shows that the CFU-GM IC 50 value for Tf-PLCaPZ NPs was nearly 6-fold higher than the corresponding IC 50 value for ZOL free (2.98 and 0.52 M, respectively).
Labeling of Autophagic Vacuoles with Monodansylcadaverine (MDC)
To quantify the induction of the autophagic process in LN229, U87 MG and U373 MG cells treated with the various compounds MDC staining was performed. Following the treatments, cells were incubated with 50 M MDC (Sigma, Milan, Italy) in PBS at 37 C for 15 min. After incubation, cells were washed with PBS, trypsinized, and immediately analyzed by flow cytometry. All fluorescences were analyzed with a FACScalibur flow cytometer (Becton Dickinson). The fluorescent emissions were collected through a 530 nm band pass filter (FL1 channel). At least 10,000 events were acquired in log mode. For the quantitative evaluation of MDC, CellQuest software (Becton Dickinson) was used to calculate mean fluorescence intensities (MFIs). The MFIs were calculated by the formula (MFItreated/MFIcontrol), where MFI treated is the fluorescence intensity of cells treated with the various compounds and MFI control is the fluorescence intensity of untreated and unstained cells as previously reported. 18 Bone Marrow CFU-GM Assay The procedure was performed according as described by Pessina et al. 19 and Kurtzberg et al. 20 Viable human bone marrow cells (purchased as frozen vials from AllCells via StemCell Technologies) were prepared with a DNase treatment (Stem Cell Technologies) and then washed in a protocol described by the vendor and cultured. The culture medium used was MethoCult GF, containing the cytokines hSCF, hGM-CSF, and hIL-3 (Stem Cell Technologies). 150 l of 20× concentration of ZOL free and NPs-ZOL Tf compounds with 150 l of a suspension of human bone marrow cells, were added to the 3 ml of MethoCult Medium and vigorously mixed using a vortex mixer. The ZOL free and NPs-ZOL Tf were used at concentrations from 0.0001 to 100 M (in half-log intervals). Final cell concentrations were 8 × 10 4 cells per plate for human cells. Tubes were then allowed to sit undisturbed for 10 to 15 min until the air bubbles dissipated. 1 ml of suspension was placed, using a syringe, in the center of duplicate treatment-labeled 35 mm dishes. Dishes were gently rotated to allow even coverage of the bottom surface of each dish, and dishes are placed in a 37 C incubator for colony formation for 15 days. Colonies were defined as clusters containing ≥30 cells. Surviving fractions were evaluated relative to untreated control. IC 50 s were obtained by using regression analysis of the logarithm of drug concentration versus CFU-GM survival fractions.
Animals
The procedures involving mice were in compliance with Regina Elena National Cancer Institute animal care guidelines and with national and international directives (D.L. March 4, 2014, no. 26; directive 2010/63/EU of the European parliament and of the council; Guide for the Care and Use of Laboratory Animals, United States National Research Council, 2011). CD-1 male nude (nu/nu) mice, 6-8 weeks old and weighing 22-24 g, purchased from Charles River Laboratories (Calco, Italy), were used.
Antitumor Efficacy of Tf-PLCaPZ NPs on GBM Xenografts Mice were injected intramuscularly (i.m.) into the hind leg muscles at 3 × 10 6 U373MG-LUC GBM cells/mouse. After 6 days (when a tumor mass of about 300 mg was evident) mice were randomized, divided in three groups and the treatment started. The following groups were evaluated: untreated, Tf-PLCaP NPs and TMZ. Mice were treated intravenously (i.v.) with Tf-PLCaPZ NPs at 20 g/mouse for three times a week for 3 consecutive weeks. This scheduling of treatment was chosen based on previous published experiments. 21 TMZ was given intraperitoneally (i.p.), representing a standard in preclinical studies on mice, at the dose of 60 mg/Kg for 5 consecutive days which is the maximum tolerated doses (MTD) as assessed in preliminary experiments.
Tumor sizes were measured three times a week in two dimensions by a caliper and tumor weight was calculated using the following formula: a × b 2 /2, where a and b are the long and short sizes of the tumor, respectively. Antitumor efficacy of treatments was assessed by the following end-points: (a) percent tumor weight inhibition (TWI%); (b) stable disease, defined as the maintenance for at least three weeks of the same tumor weight as the start of treatment; (c) complete tumor regression, defined as tumor disappearance, as evaluated by palpability, lasting for at least 10 days during or after treatment period.
In Vivo Imaging of Tumors
Mice bearing U373MG-LUC tumors were imaged using the IVIS imaging system 200 series (Caliper Life Sciences, Hopkinton, MA, USA). Briefly, mice (previously treated as reported above) were anesthetized with a combination of tiletamine-zolazepam (Telazol, Virbac, Carros, France) and xylazine (xylazine/Rompun BAYER) given intramuscularly at 2 mg/kg. Then mice were injected intraperitoneally with 150 mg/kg D-luciferin (Caliper Life Sciences), and imaged in the supine position 10 min after luciferin injection. Imaging was performed at baseline before the start compound administration and several times during the experiment. Data were acquired and analyzed using the living image software version 3.0 (Caliper Life Sciences). Each experimental group included six mice and experiments were repeated two times.
Statistical Analysis
For comparison of several groups, one-way ANOVA for multiple groups, followed by Newmane-Keuls test if P < 0 05 was performed using the GraphPad Prism version 5.0 software (GraphPad Software, Inc, San Diego, CA). All numerical data are expressed as mean ± SD, n = 3 or more, from 3 different experiments. The Student's t-test (unpaired, two-tailed) was used for comparing statistical differences in tumor weights. Any p values less than 0.05 was considered statistically significant.
RESULTS
Here, in order to improve the specificity and the delivery of ZOL in GBM cells, we upgraded the earlier developed PLCaPZ NPs with human Tf. Physical characteristics of Tf-PLCaPZ NPs, i.e., size, surface charge and ZOL loading efficiency, are shown in Table I . When Tf was added to PEGylated cationic liposomes, a dramatic decrease in the net positive charge of the liposomes was observed. No significant change in the particles mean diameter as well as in the size distribution of the NPs was observed after functionalization of the PLCaPZ NPs with Tf. In particular, Tf-PLCaPZ NPs had a mean diameter of about 147 nm with a very narrow size distribution (PI < 0 2). Furthermore, chromatographic analysis of non-complexed ZOL showed an actual loading of ∼100 g of ZOL/mg lipids, corresponding to a complexation efficiency of about 100%, in both PLCaPZ NPs and Tf-PLCaPZ NPs. Moreover, about the 46 ± 0 6% of the Tf added in the preparation resulted electrostatically bound to the surface of NPs, while the remaining part was found in solution associated to the NPs.
Then, in order to evaluate the hemolytic activity of those NPs in human blood, hemolysis assay was performed (Fig. 2) . Interestingly, in all the cases no significant hemolytic activity was observed after incubation of a dispersion containing erythrocytes with the NPs developed. It is worth to note that after incubation with the NPs functionalized with Tf an additional significant reduction of the hemolytic activity compared to not targeted PLCaPZ NPs (p < 0 001) was observed. 
Formulations
Diameter (nm) ± SD I.P. ± SD ± SD PLCaPZ NPs 147 5 ± 7 1 0 15 ± 0 06 +17 5 ± 5 6 Tf-PLCaPZ NPs 147 7 ± 15 0 0 17 ± 0 05 +11 3 ± 1 1
Transferrin Receptor Expression in GBM Cells
We have evaluated the anti-proliferative effects of free ZOL and of the different NP formulations on the three GBM cell lines with MTT viability assay. The cells were treated for 72 h and then the viability was evaluated.
We have identified the concentration of the drugs able to inhibit the 50% of cell growth (IC 50 ) (Table II) . We observed that the encapsulation of ZOL into NPs increased the cytotoxic activity of ZOL by reducing the IC 50 . Free ZOL induced a 50% growth inhibition at a concentration of 22, 69.8 and 46 M (IC 50 in LN229, U87 MG and U373 MG, respectively, and this effect was enhanced when ZOL was encapsulated into NPs. In fact, PLCaPZ NPs showed an IC 50 equal to 9 M in LN229, 18 M in U87 MG and 20 M in U-373 MG, that was significantly lower than that one induced by free drug (Table II) . Tf-PLCaPZ NPs caused a significant decrease of the IC 50 compared to free ZOL but not respect to PLCaPZ NPs (11 M for LN229, 37 M for U87 MG and 39 M for U373 MG) (Table II) . In all the cases, plain NPs did not induce a significant growth inhibition demonstrating a very low cytotoxicity. Thereafter, we investigated the expression of Tf type 1 receptor (CD71) in GBM cells by Western Blot. LN229, U87 MG and U373 MG cells were harvested after 72 h of treatment with ZOL at a concentration equal to its IC 50 at 72 h for each cell line. We used prostate cancer cells PC-3 as a positive control. The receptor was expressed in all GBM cell lines at baseline and treatment with ZOL did not significantly modulate TfR expression. As expected, PC-3 expressed the receptor at high levels. The expression of -tubulin was assessed as loading control (Fig. 3(A) ).
On the bases of these results, we evaluated the basal expression of the TfR both on the cell membrane and at the intracellular level on all GBM cell lines by FACS analysis. The receptor was expressed at higher levels in LN229 both on the membrane and at the intracellular level while the U373 MG and U87 MG cells expressed the receptor at lower levels both on the membrane and at intracellular level (Figs. 3(B and C) ). Interestingly, LN229 cell line was also the most responsive to the inhibitory effects of Tf-PLCaPZ NPs, as shown in Table II . In conclusion, the receptor was expressed in all GBM cell lines but at higher levels in LN229 compared to U373 MG and U87 MG.
Tf-PLCaPZ NPs Uptake and Intracellular Distribution
To investigate the NPs uptake and the intracellular distribution, green fluorescently labeled NPs were used on LN229 cells. The fluorescence associated to the cells was evaluated by both FACS and confocal laser scanning microscopy (CLSM). FACS analysis of LN229 cells after 1, 3, 6, 24, 48, and 72 h hours of incubation with fluorescently labeled NPs was performed (Fig. 4) . LN-229 22 ± 0 01 9 0 ± 0 06 ≫120 ± 0 01 11 0 ± 0 03 ≫120 ± 0 03 U-87 MG 69 8 ± 0 02 18 0 ± 0 01 ≫120 ± 0 04 39 0 ± 0 04 ≫120 ± 0 01 U-373 MG 46 0 ± 0 04 20 0 ± 0 03 ≫120 ± 0 03 37 0 ± 0 02 ≫120 ± 0 07
In particular, after 6 h of incubation with PLCaPZ NPs or Tf-PLCaPZ NPs, FACS analysis revealed the highest increase in the % of mean fluorescence intensity (MFI) associated to the cells, thus showing NPs uptake as compared with the untreated control (Fig. 4(A) ). MFI of control was considered as 100%; after 6 h of cell incubation Tf-PLCaPZ NPs induced a significantly higher MFI increase (450%) as compared with PLCaPZ NPs (370%) (Fig. 4(B) ). In both cases, MFIs decreased in a timedependent manner after 24 h. In order to investigate if the interaction of Tf-PLCaPZ NPs with cells is really mediated by TfR, we preincubated LN229 cells with increasing concentrations of anti-CD71 to block TfR and then we treated cells with Tf-PLCaPZ NPs IC 50 or PLCaPZ NPs for 6 h. FACS analysis showed that pre-incubation with 30 g/ml anti-CD71 reduced MFI of about 40%, thus showing a decreased Tf-PLCaPZ NPs uptake as compared with cells treated only with Tf-PLCaPZ NPs; MFI after 6 h incubation with Tf-PLCaPZ NPs was considered as 100% uptake (Fig. 5) . On the other hand, PLCaPZ NPs uptake was not affected by blocking Tf receptor (Fig. 6) . The uptake and intracellular distribution of fluorescently labeled NPs after 6 and 72 h of incubation was studied also by confocal microscopy. After 6 h, CLSM results showed a widespread and intense fluorescence, with perinuclear green spots into the cytoplasm, for cells incubated with Tf-PLCaPZ NPs (Fig. 4(C) ). Cells treated with PLCaPZ NPs, compared to Tf-PLCaPZ NPs, evidenced a significant lower fluorescence intensity. A green fluorescence was observed also in the cells incubated with plain NPs and in particular, plain Tf-PLCaP NPs showed the higher fluorescence intensity (Fig. 4(C) ). After 72 h, the fluorescence intensity decreased in all the cases (Fig. 4(C) ). Therefore, the intracellular uptake of NPs could contribute to increasing the amount of ZOL that reaches its cytoplasmic targets.
Effects of Tf-PLCaPZ NPs on the Differentiation of GBM Cells
After 48 h of treatment with Tf-PLCaPZ NPs at a concentration corresponding to its IC 50 , we observed that LN229 cells changed their shape. In details, Tf-PLCaPZ NPs induced a significant cell elongation that was higher than that one induced by free ZOL and PLCaPZ NPs. As cell elongation can be correlated with cell differentiation, we have studied two differentiation markers, Olig2 and GFAP that were assessed at CLSM. In details, Olig2 showed a well distributed higher fluorescence for cells incubated with Tf-PLCaPZ NPs as compared to free ZOL or PLCaPZ NPs (Fig. 7) . Cells treated with Tf-PLCaPZ NPs evidenced widespread lower fluorescence intensity for GFAP as compared to Olig2 expression (Fig. 7) . These data suggest that the treatment of LN229 cells with ZOL induced a differentiation towards an oligodendrocyte phenotype and that this effect was strongly enhanced by the delivery of the agent by Tf-PLCaPZ NPs. Moreover, we have found that the Tf-PLCaPZ NPs have lower toxicity than free ZOL.
Toxicity of the NPs on GM-CFUs
A major goal in the preclinical drug development is to predict whether new agents or new formulations will be clinically toxic to the bone marrow. Bone marrow is critically sensitive to many cytotoxic agents and myelotoxicity represents one of the limitations to the use of full doses of antineoplastic drugs, including ZOL. For these reasons, we compared the toxicity of ZOL and Tf-PLCaPZ NPs on human bone marrow by using the well-validated CFU-GM assay. Human bone marrow cells were treated in vitro with ZOL either free or encapsulated in Tf-PLCaPZ NPs at doses from 0.0001 to 100 M and surviving fractions were determined. As it is evident from Figure 8 the encapsulation significantly reduced the myelotoxicity of ZOL. In fact, the interpolation on the curve shows that the CFU-GM IC 50 value for Tf-PLCaPZ NPs was nearly 6-fold higher than the corresponding IC 50 value for ZOL free (2.98 and 0.52 M, respectively).
Anti-Proliferative Effects of the Sequential Administration of Tf-PLCaPZ NPs and TMZ on GBM Cells
A conventionally used cytostatic agent for the treatment of GBM in combination with radiation therapy or alone after surgery and radiotherapy is TMZ. On these bases, we evaluated the growth inhibition induced by TMZ on the three GBM cell lines. After 72 h the IC 50 s of TMZ were 176 M, 95 M and 110 M for LN-229, U87 MG, U373 MG, respectively. These data were used to assess the effects of TMZ in combination with the different NP formulations and in different sequences of cell exposure. In details, we added to the cells TMZ for 72 h and NPs for 48 h or vice versa or we simultaneously treated the cells with TMZ and NP formulations for 72 h. Analyzing the results, when free ZOL or the different NPs were simultaneously added to the cells with TMZ, a significant reduction of the antiproliferative activity, compared to the administration of the single agents, was observed. A slight synergistic effect was observed both in LN229 and in U-373 MG cells, after treatment with the combinations PLCaPZ NPs/TMZ and Tf-PLCaPZ NPs/TMZ (Fig. 9) . On the contrary, better results were obtained when TMZ was added to the cells before both free ZOL, PLCaPZ NPs or Tf-PLCaPZ NPs. In this case, a synergistic effect was observed in all the three GBM cell lines. Interestingly, TMZ followed by Tf-PLCaPZ NPs was strongly synergistic on LN229 cells (CI 50 = 0 42). Similarly, TMZ followed by free ZOL was highly synergistic on the U87 MG cells (CI 50 = 0 43). The reverse sequences (ZOL, PLCaPZ NPs or Tf-PLCaPZ NPs followed by TMZ) were in almost all the cases antagonistic or additive on the inhibition of the proliferation of all the GBM cell lines. Only the sequences Tf-PLCaPZ NPs/TMZ and PLCaPZ NPs/TMZ were strongly synergistic on the growth inhibition of LN229 and U373 MG cells, respectively, with an CI 50 = 0 30 and CI 50 = 0 43, respectively (Fig. 9) . Subsequently, we calculated the potentiation factor (PF) for treatments that showed synergism. The PF is the ratio between the IC 50 of the drug used alone and the IC 50 of the drug used in the combination: if PF is greater than 1, it means that the drug in combination determines its anti-proliferative effect at a lower concentration compared to the drug alone. In our experimental conditions, PF was much more higher when TMZ was added to the cells before the other drugs (ZOL, PLCaPZ NPs, Tf-PLCaPZ NPs). These data suggest that Tf-PLCaPZ NPs strongly potentiated the anticancer effects of TMZ when they are added to the cells after the cytotoxic drug. 
Effects of TMZ/NPs Synergism on Apoptosis and Autophagy
In order to investigate the biochemical mechanisms on the basis of the growth inhibition, we evaluated the effects of ZOL, PLCaPZ NPs, Tf-PLCaPZ NPs and the sequence TMZ followed by Tf-PLCaPZ NPs (TMZ → Tf-PLCaPZ NPs) on apoptosis by double labelling with Annexin V and propidium iodide at FACS. After 72 h of treatment, we found that the different treatments induced no apoptosis in U373 MG cells with the exception of the sequence TMZ → Tf-PLCaPZ NPs which induced an about 13% of apoptosis in cell population (Fig. 10) . When U87MG cells were treated with ZOL, PLCaPZ NPs, Tf-PLCaPZ NPs and the sequence, only 4.2%, 2.3%, 0.6% and 2.5% of apoptosis, respectively, was detected. On the contrary in LN229 cells, Tf-PLCaPZ NPs induced apoptosis in 6.4%, ZOL in 5.4%, PLCaPZ NPs in 3.5% and the sequence in 5% of cells, respectively, as compared with the untreated control (Figs. 10(A and B) ). On the other hand, Tf-PLCaPZ NPs induced a higher increase of necrosis (17%) as compared to ZOL (5.1%), PLCaPZ NPs (4.3%) and the sequence (7.4%). Necrosis increased also in U373 MG and in U87 MG and it was higher in TMZ → TfPLCaPZ NPs treated cells. In details, 10.2%, 5.5%, 12.7% and 14.3% of U373 MG cells was necrotic when the cells were treated with ZOL, PLCaPZ NPs, Tf-PLCaPZ NPs and TMZ/Tf-PLCaPZ NPs, respectively, while in U87 MG, ZOL induced necrosis in 15.1% of cell population, PLCaPZ NPs in 7.7%, Tf-PLCaPZ NPs in 9.9% and the sequence in 15.3% as compared to control (Fig. 10) . On these bases, we investigated whether NPs and the synergistic sequence TMZ followed by Tf-PLCaPZ NPs were able to induce autophagy. To ascertain whether the presence of necrosis in Tf-PLCaPZ NPs and TMZ/Tf-PLCaPZ NPs treated cells was due to the induction of autophagy, the autofluorescent agent monodansylcadaverine (MDC), a selective marker for AVOs was used. Figure 6 shows the quantitative evaluation of MDC staining performed by FACS and expressed as % MFI of control. We again found that ZOL induced a slight increase in AVOs formation in LN229 (230% of control) and U87 MG (180% of control) but not in U373 MG; this increase was more prominent in PLCaPZ NPs and Tf-PLCaPZ NPs-treated GBM cells. In details, PLCaPZ NPs induced an about 450%, 340% and 205% increase of MFI versus control in LN229, U87 MG and U373 MG, respectively, while Tf-PLCaPZ NPs induced an about 500% increase of MFI in LN229, 350% in U87 MG and 184% in U373 MG, respectively (Fig. 11) . This effect was strongly potentiated by the sequence TMZ → Tf-PLCaPZ NPs in U373 MG (260% MFI of control) but not in LN229 (390%) and U87 MG (320%) cells.
Antitumor Efficacy of Tf-PLCaPZ NPs on Bioluminescent GBM Xenografts
We have already reported that ZOL encapsulated in NPs functionalized with Tf have a strong antitumor activity against GBM xenografts and that this activity is higher Figure 9 . IC 50 values of the different combinations. For the evaluation of the synergism between the different NP formulations or free ZOL and TMZ on the growth inhibition of GBM cells, the cells were seeded in 96-multiwell plates at the density of 2 × 103 cells/well. After 24 h of incubation at 37 C the cells were treated with different concentrations of Tf-PLCaPZ NPs, PLCaPZ NPs, free ZOL, TMZ. Alternatively, cells were treated simultaneously with TMZ and NP formulations or sequentially with TMZ followed by NP formulations and conversely. The evaluation of synergism was performed using dedicated software, CalcuSyn (Biosoft, Ferguson, MO), which measures the interaction between the drugs by calculating the indexes of combination (CIs). CI values <1, 1 and >1 indicate synergism, additivity and antagonism, respectively. than un-targeted PLCaPZ NPs. 21 In view of a possible application of this new formulation in a clinical setting, here we have compared the in vivo efficacy of Tf-PLCaPZ NPs with TMZ, which represents a gold-standard for GBM treatment in humans. As is shown in Figure 12 (A), the efficacy of TMZ was very limited (TWI 15%) since after an initial reduction of the tumor growth, tumors rapidly progressed. Tf-PLCaPZ NPs confirms the high therapeutic efficacy against GBM xenogratfs since this treatment produced a significant (P < 0 001 vs. untreated and TMZtreated group) tumor weight inhibition of about 45% in mice (panel A). Interestingly, bioluminescence analysis performed at different times on whole mice shows that Tf-PLCaPZ NPs even induced one stable disease and one complete tumor regression as shown in panel B, thus highlighting the potential of this formulation as a therapeutic tool.
DISCUSSION
In the present study, we have proposed a new strategy to inhibit GBM cells growth. In a previous work, we demonstrated that self-assembling NPs could be used to successfully deliver ZOL in different cell lines, with a strong potentiation of its anti-cancer effect. 11 These effects were then confirmed in vivo in an experimental model of prostate cancer. 12 On the basis of these interesting results, it should be attractive to use this technology for the delivery of ZOL also in tumors as GBM that, at the moment, are very difficult to treat, also in vitro. To this aim, earlier developed self-assembling NPs have been potentiated in order to target TfR, which is overexpressed in different cancer cells, such as GBM. Tf has been successfully used for active targeting of cancer cells and Tf-modified NPs are at the moment in clinical trials. 22 The biological significance of Tf and its receptor has been characterized and its relevance when applied to targeting strategies has been widely reported. 22 It has been found a direct correlation between increased expression of Tf receptor and the levels of malignancy in a wide range of tumors, including glioma. 23 In addition, Tf is the major peptide involved in the transportation of iron from the blood into the brain. 24 All this knowledge about the physiological function and expression of Tf and its role in drug delivery provides rationale for the development of Tf-targeted NPs to improve the delivery of a promising anti-cancer agent, such as ZOL, in GBM cells.
The previously proposed NPs were developed by simply mixing, in the first step, ZOL with CaP NPs to form complexes, due to the high affinity of ZOL for Ca 2+ . In the second step, the resulting complex is mixed with cationic/PEGylated lipids, in order to cover the ZOL/CaP complex and to provide a lipid and PEGylated shell with stealth properties. Previously we demonstrated that liposomes, once mixed with CaPZ, disassemble to provide nanoparticles with a mean diameter of about 150 nm and a very narrow size distribution. 11 In this study, Tf was included in the formulation by electrostatic interaction with cationic liposomes, as previously showed by other authors. 25 The electrostatic interaction was preferred to the chemical conjugation of Tf to the liposomes in order to have a NP formulation that can be prepared before use starting from 4 components already available on the market (i.e., ZOL and Tf) or easily manufactured at large scale (i.e., CaP NPs and cationic PEGylated liposomes). This approach should facilitate the clinical development of this formulation by overcoming storage issues (NPs are prepared before use) and facilitating the scale-up process. The inclusion of Tf in the protocol and Tf mixing with PEGylated cationic liposomes before complexation with CaPZ, did not result in a significant change in terms of mean diameter, P.I. and ZOL encapsulation efficiency. Tf complexation with PEGylated cationic liposomes resulted in a strong decrease of the , thus indicating efficient charge shielding, reasonably due to the presence of Tf on the vesicle surface.
The instability of therapeutic NPs in the blood is considered to be one of the serious limitations in their clinical use. In particular, carrier based on cationic lipids often present hemolytic activity at certain concentrations. 26 Our results revealed that, at the concentration used in the in vitro studies, no targeted PLCaPZ NPs showed a limited hemolytic activity (of ∼5%). The presence of PEG chain in the NPs formulation could contribute to the low hemolytic activity of these NPs, probably due to a shielding effect on the surface positive charge. 27 Interestingly, Tf-PLCaPZ NPs showed almost no hemolytic activity, since, according to ASTM F 756-08 a hemolytic activity less than 2% is generally regarded to a non-toxic effect level. 28 Since Tf possesses a net negative charge, its introduction on the surface of the NPs reduced significantly the rate of hemolysis compared to no-targeted PLCaPZ NPs (∼1% vs. ∼5%, respectively). Therefore, the significant low rate of hemolysis (p < 0 001) observed by using Tf-PLCaPZ NPs can be correlated to the ability of Tf to shield more efficiently the positive charge of the NPs. In addition, the use of a physiological molecule, such as Tf, could further contribute to a biocompatibility of these NPs.
Then, we investigated the effect of NPs functionalization in GBM cell lines. We evaluated if the GBM cells expressed significant levels of TfR by Western blot analysis. Our results showed that all the three GBM cell lines expressed TfR, with the highest levels in LN229 cells. Interestingly, in LN229 cells, we observed a significant uptake of Tf-PLCaPZ NPs, visualized by confocal microscopy and FACS analysis, suggesting a correlation between the higher levels of Tf in this cell line and the cell internalization of Tf-PLCaPZ NPs. Moreover, if compared to no targeted PLCaPZ NPs, the cell uptake of Tf-PLCaPZ NP was significantly enhanced. Richard et al. 29 found that for Tat and (Arg) 9 , even the cell-fixation protocols commonly used to evaluate uptake by fluorescence microscopy caused an artifactual redistribution of these peptides into the nucleus and gave rise to altered images as compared with the experiments made on unfixed cells. This was not observed for classical endocytic markers such as transferrin and FM 4-64. Enhanced Tf-PLCaPZ uptake observed by us could not be attributed to fixation artifacts, since we found the presence of the punctate cytoplasmic labeling characteristic of endocytic uptake and an increase of Tf-PLCaPZ cellular uptake also by FACS analysis on unfixed cells. It is worthy of note that the IC 50 of Tf-PLCaPZ NPs was slightly higher than PLCaPZ NPs; these results could be explained by the presence of free Tf associated to the NPs (about 54%) following preparation. In this regard, we have found that the exposure of glioblastoma cells to an antibody raised against TfR significantly reduces the uptake of NPs thus suggesting a lower interaction of NPs with the cells. The excess of Tf released in the medium could therefore interfere with the binding of the functionalized NPs to the cells explaining the nonsuperiority of the anti-cancer effect induced by the NPs in in vitro setting. However, the design of NPs functionalized with Tf, in our experimental model, is aimed to facilitate the BBB crossing and to target GBM cells placed in the brain in in vivo setting where free Tf is diluted in the body fluids where it is expected not interfering with the interaction processes.
Moreover, Tf-PLCaPZ NPs were able to induce morphological changes in LN229 cells. In particular, Tf-PLCaPZ NPs elicited a significant cell elongation that was much higher than the one induced by free ZOL or by PLCaPZ NPs. In order to confirm these changes in cell shape, we used vimentin to label cytoplasm; vimentin filaments have been shown to be present in podosomes of macrophages. 30 It is well established that intermediate filaments are involved in regulating cell shape and tissue homeostasis. Interestingly, Schoumacher et al. 31 showed that vimentin was present in mature invadopodia and an intact vimentin network was required for invadopodia elongation. As cell elongation can be correlated with cell differentiation, we have subsequently analyzed the levels of two differentiation markers, Olig2 and GFAP. GBM is an anaplastic brain tumor characterized by poorly differentiated neoplastic cells 32 and it is highly refractory to conventional treatments. It has been found a direct correlation between Olig2 and GFAP levels and the response to chemotherapeutic agents. In particular, glial tumors characterized by high levels of Olig2 and low levels of GFAP (Olig2+/GFAP−), a condition usually found in oligodendroglioma, are characterized by better prognosis, higher chemosensitivity and better survival. 33 Interestingly, we found that, Tf-PLCaPZ NPs treated LN229 cells expressed higher levels of Olig2 rather than GFAP as compared with free ZOL or PLCaPZ NPs. These results suggest that treatment with Tf-PLCaPZ NPs could induce oligodendrocytic differentiation of LN229 GBM cells.
In a second phase of the study, we investigated the possibility to combine Tf-PLCaPZ NPs with a chemotherapeutic agent, TMZ. TMZ is currently the first line choice for the treatment of GBM, together with radiotherapy. However, its effectiveness is often limited and it seems to act above all as radiosensitizers in the classical Stupp schedule that represents the gold standard in the treatment of GBM in the first line of treatment. 34 In our preliminary study, we found that the treatment of GBM cells with free TMZ was characterized by an in vitro refractoriness to TMZ. On the contrary, treatment with free ZOL or ZOL incorporated in either PLCaPZ NPs or Tf-PLCaPZ NPs induced a more potent effect on the growth inhibition of GBM cells if compared to TMZ. In order to investigate if treatment with NP formulations containing ZOL could sensitize GBM cells to TMZ, synergistic studies were performed. Previously, it has been reported a synergistic effect of ZOL in combination with conventional cytotoxic drugs (doxorubicin or docetaxel) in particular when these were added to either breast cancer cells or prostate cancer cells before ZOL. 35 Here, we have studied the synergistic effect of ZOL and TMZ in different sequences of administration. In all the GBM cells, we found a synergistic effect when ZOL was added after TMZ. On the other hand, the concomitant treatment of ZOL and TMZ did not result in a substantial synergism. It is worth to note that in all the cases, the treatment of GBM cells with ZOL-containing NPs potentiated the synergistic effect.
Interestingly, Tf-PLCaPZ NPs appeared to be more active when administered in combination with TMZ on LN-229 cells that express higher levels of TfR. These results suggest that the high expression of TfR may improve binding and subsequent internalization of Tf-functionalized NPs and consequently potentiate the antitumor activity of ZOL. It is also interesting to note that, only when using Tf-PLCaPZ NPs, even in the reverse order of administration with TMZ, is possible to find a strong synergism on LN-229 cells.
All the treatments were not able to induce significant apoptosis. On the other hand, the sequential treatment with TMZ followed by Tf-PLCaPZ NPs potentiated the occurrence of autophagy (an alternative programmed cell death mechanism), in particular in U373 MG cells.
A hallmark of most of anti-neoplastic drugs is represented by systemic toxicity, including bone marrow toxicity that strongly reduces their therapeutic window. Moreover, it has been reported that liposomal formulations of ZOL, able to modify pharmacokinetic and biodistribution of this agent, can increase drug toxicity thus hampering clinical application of this delivery systems. 36 Interestingly, in the present study we found that the developed Tf-PLCaPZ NPs had an almost 6-fold lower IC 50 against human bone marrow CFU-GM than those observed after treatment with free ZOL. Moreover, the haemolytic potential 26 28 of Tf-PLCaPZ NPs is indeed lower than no target PLCaPZ NPs.
The observation that Tf-PLCaPZ NPs were highly effective in reducing the growth of GBM xenografts and the poor response of tumors to TMZ treatment, strengthens the potential of this formulation for the application in humans.
CONCLUSIONS
We have proposed a new strategy to efficiently use ZOL for the treatment of GBM. The developed Tf-PLCaPZ NPs were obtained by easy upgrade of the NPs with specific ligands maintaining high ZOL incorporation, high colloidal stability and small particle sizes. The Tf-PLCaPZ NPs were able to efficiently accumulate into LN229 GBM cells and to consequently inhibit their growth. In addition, the treatment with Tf-PLCaPZ NPs mediated a potent sensitization of GBM cells to non-effective doses of TMZ. Finally, they exhibited a good efficacy in vivo. These promising results open a new perspective to use this tiny but mighty NPs for the treatment of GBMs that negatively respond to the current therapies.
